WeTrials
Active, not recruiting

A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer

What is this study?

This study is testing a drug called dostarlimab for a specific type of rectal cancer that has not been treated yet. The main goal is to see if this treatment works so well that patients can avoid standard treatments like chemotherapy, radiation, and surgery.

Who can participate?

This study is no longer enrolling new participants. It enrolled adults with stage II or III rectal cancer that had not been treated yet (no earlier radiation, chemotherapy or surgery for it) and had not spread to distant parts of the body. Their tumors had to test dMMR (mismatch repair deficient) or MSI-H (microsatellite instability-high), features found in about 3 in 100 locally advanced rectal cancers. People with an active autoimmune disease treated in the past 2 years, a history of lung inflammation (pneumonitis or interstitial lung disease), or severe immune side effects from earlier immunotherapy could not take part.

What will happen?

Participants will receive dostarlimab, an immunotherapy medicine that helps your immune system fight the cancer. If the treatment makes the cancer completely disappear, you will be closely monitored with regular check-ups instead of having surgery.

Where and when?

The study is running at 42 sites in 10 countries: 7 in the United States (Los Angeles, Albuquerque, New York, Pittsburgh, Nashville, Dallas and Richmond), 4 in Canada (Ottawa, Toronto, Montreal and Sherbrooke), and others in Spain, France, Germany, Japan, South Korea, Italy, the United Kingdom and the Netherlands. It is still active but no longer enrolling new participants. Based on early results from this study, the FDA granted accelerated approval to dostarlimab (Jemperli) on October 19, 2026 for adults with stage II or III dMMR/MSI-H locally advanced rectal cancer. Continued approval may depend on further results.

Key Points
  • 1Tests dostarlimab immunotherapy as a standalone treatment for rectal cancer
  • 2Aims to help patients safely avoid chemotherapy, radiation, and surgery
  • 3Currently active but not open for new participants

Related video

Rectal Cancer (dMMR): FDA Approves an Immunotherapy That May Let Some Skip Surgery

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Neoplasms, Rectal

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.